Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients
Purpose This study aimed to assess whether the whole body metabolic active tumour volume (MTV WB ), quantified on staging [ 18 F]FDG PET/CT, could further stratify stage IV non-small cell lung cancer (NSCLC) patients. Methods A group of 160 stage IV NSCLC patients, submitted to staging [ 18 F]FDG PE...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2021-12, Vol.147 (12), p.3601-3611 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3611 |
|---|---|
| container_issue | 12 |
| container_start_page | 3601 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 147 |
| creator | Rocha, Ana Luísa Gomes da Conceição, Mauro Alessandro Monteiro da Cunha Sequeira Mano, Francisco Xavier Proença Martins, Helder Carvalho Costa, Gracinda Maria Lopes Magalhães Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa Lapa, Paula Alexandra Amado |
| description | Purpose
This study aimed to assess whether the whole body metabolic active tumour volume (MTV
WB
), quantified on staging [
18
F]FDG PET/CT, could further stratify stage IV non-small cell lung cancer (NSCLC) patients.
Methods
A group of 160 stage IV NSCLC patients, submitted to staging [
18
F]FDG PET/CT between July 2010 and May 2020, were retrospectively evaluated. MTV
WB
was quantified. Univariate and multivariate Cox regressions were carried out to assess correlation with overall survival (OS). C-statistic was used to test predictive power. Kaplan–Meier survival curves with Log-Rank tests were performed to compute statistical differences between strata from dichotomized variables and to calculate the estimated mean survival times (EMST). Survival rates at 1 and 5 years were calculated.
Results
MTV
WB
was a statistically significant predictor of OS on univariate (
p
|
| doi_str_mv | 10.1007/s00432-021-03799-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2576914977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2588778406</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-50198556fbfd9c605fddf4e10677e798e85d8688a815eb90b33fc1b2003e69b63</originalsourceid><addsrcrecordid>eNp9kUFrFDEYhoMouLb-AU8BL16m_TLZTJKjrN1aaKuHbS8iIZP5sk6ZyWyTTEtv_vRmu4LgwUvCF57n5SMvIR8YnDAAeZoAlryuoGYVcKl19fiKLNj-iXEuXpMFMMkqUbPmLXmX0h2UWch6QX5fYbbtNPSOWpf7B6R5Hqc50odpmEek97MNufc9dnQK9AdT65_rL-f0-9nmdLWhfo75F0aacrQvVKKb66sy2i3Si1saplCl0Q4DdViOYQ5b6mxwRdkVAUNOx-SNt0PC93_uI3KzPtusvlaX384vVp8vK8dFnSsBTCshGt_6TrsGhO86v0QGjZQotUIlOtUoZRUT2GpoOfeOtTUAx0a3DT8inw65uzjdz5iyGfu038oGnOZkaiEbzZZayoJ-_Ae9Kz8SynaFUkpKtYR9YH2gXJxSiujNLvajjU-GgdmXYg6lmFKKeSnFPBaJH6RU4LDF-Df6P9Yzv42PZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2588778406</pqid></control><display><type>article</type><title>Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients</title><source>SpringerNature Journals</source><creator>Rocha, Ana Luísa Gomes ; da Conceição, Mauro Alessandro Monteiro ; da Cunha Sequeira Mano, Francisco Xavier Proença ; Martins, Helder Carvalho ; Costa, Gracinda Maria Lopes Magalhães ; Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa ; Lapa, Paula Alexandra Amado</creator><creatorcontrib>Rocha, Ana Luísa Gomes ; da Conceição, Mauro Alessandro Monteiro ; da Cunha Sequeira Mano, Francisco Xavier Proença ; Martins, Helder Carvalho ; Costa, Gracinda Maria Lopes Magalhães ; Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa ; Lapa, Paula Alexandra Amado</creatorcontrib><description>Purpose
This study aimed to assess whether the whole body metabolic active tumour volume (MTV
WB
), quantified on staging [
18
F]FDG PET/CT, could further stratify stage IV non-small cell lung cancer (NSCLC) patients.
Methods
A group of 160 stage IV NSCLC patients, submitted to staging [
18
F]FDG PET/CT between July 2010 and May 2020, were retrospectively evaluated. MTV
WB
was quantified. Univariate and multivariate Cox regressions were carried out to assess correlation with overall survival (OS). C-statistic was used to test predictive power. Kaplan–Meier survival curves with Log-Rank tests were performed to compute statistical differences between strata from dichotomized variables and to calculate the estimated mean survival times (EMST). Survival rates at 1 and 5 years were calculated.
Results
MTV
WB
was a statistically significant predictor of OS on univariate (
p
< 0.0001) and multivariate analyses (
p
< 0.0001). The multivariate model with MTV
WB
(Cindex ± SE = 0.657 ± 0.024) worked significantly better as an OS predictor than the cTNM model (Cindex ± SE = 0.544 ± 0.028) (
p
= 0.003). An EMST of 29.207 ± 3.627(95% CI 22.099–36.316) months and an EMST of 10.904 ± 1.171(95% CI 8.609–13.199) months (Log-Rank
p
< 0.0001) were determined for patients with MTV
WB
< 104.3 and MTV
WB
≥ 104.3, respectively. In subsamples of stage IVA (cut-off point = 114.5) and IVB patients (cut-off point = 191.1), statistically significant differences between EMST were also reported, with
p-values
of 0.0001 and 0.0002, respectively. In both substages and in the entire cohort, patients with MTV
WB
≥ cut-off points had lower EMST and survival rates.
Conclusion
Baseline MTV
WB
, measured on staging [
18
F]FDG PET/CT, further stratifies stage IV NSCLC patients. This parameter is an independent predictor of OS and provides valuable prognostic information over the 8th edition of cTNM staging.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-021-03799-w</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Hematology ; Internal Medicine ; Lung cancer ; Medicine ; Medicine & Public Health ; Metabolism ; Non-small cell lung carcinoma ; Oncology ; Original Article – Cancer Research ; Small cell lung carcinoma ; Statistical analysis ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2021-12, Vol.147 (12), p.3601-3611</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-50198556fbfd9c605fddf4e10677e798e85d8688a815eb90b33fc1b2003e69b63</citedby><cites>FETCH-LOGICAL-c352t-50198556fbfd9c605fddf4e10677e798e85d8688a815eb90b33fc1b2003e69b63</cites><orcidid>0000-0001-7836-8161 ; 0000-0002-2014-0399 ; 0000-0003-3051-4152 ; 0000-0002-4964-9746 ; 0000-0001-9855-0454 ; 0000-0003-3270-0119</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-021-03799-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-021-03799-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Rocha, Ana Luísa Gomes</creatorcontrib><creatorcontrib>da Conceição, Mauro Alessandro Monteiro</creatorcontrib><creatorcontrib>da Cunha Sequeira Mano, Francisco Xavier Proença</creatorcontrib><creatorcontrib>Martins, Helder Carvalho</creatorcontrib><creatorcontrib>Costa, Gracinda Maria Lopes Magalhães</creatorcontrib><creatorcontrib>Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa</creatorcontrib><creatorcontrib>Lapa, Paula Alexandra Amado</creatorcontrib><title>Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
This study aimed to assess whether the whole body metabolic active tumour volume (MTV
WB
), quantified on staging [
18
F]FDG PET/CT, could further stratify stage IV non-small cell lung cancer (NSCLC) patients.
Methods
A group of 160 stage IV NSCLC patients, submitted to staging [
18
F]FDG PET/CT between July 2010 and May 2020, were retrospectively evaluated. MTV
WB
was quantified. Univariate and multivariate Cox regressions were carried out to assess correlation with overall survival (OS). C-statistic was used to test predictive power. Kaplan–Meier survival curves with Log-Rank tests were performed to compute statistical differences between strata from dichotomized variables and to calculate the estimated mean survival times (EMST). Survival rates at 1 and 5 years were calculated.
Results
MTV
WB
was a statistically significant predictor of OS on univariate (
p
< 0.0001) and multivariate analyses (
p
< 0.0001). The multivariate model with MTV
WB
(Cindex ± SE = 0.657 ± 0.024) worked significantly better as an OS predictor than the cTNM model (Cindex ± SE = 0.544 ± 0.028) (
p
= 0.003). An EMST of 29.207 ± 3.627(95% CI 22.099–36.316) months and an EMST of 10.904 ± 1.171(95% CI 8.609–13.199) months (Log-Rank
p
< 0.0001) were determined for patients with MTV
WB
< 104.3 and MTV
WB
≥ 104.3, respectively. In subsamples of stage IVA (cut-off point = 114.5) and IVB patients (cut-off point = 191.1), statistically significant differences between EMST were also reported, with
p-values
of 0.0001 and 0.0002, respectively. In both substages and in the entire cohort, patients with MTV
WB
≥ cut-off points had lower EMST and survival rates.
Conclusion
Baseline MTV
WB
, measured on staging [
18
F]FDG PET/CT, further stratifies stage IV NSCLC patients. This parameter is an independent predictor of OS and provides valuable prognostic information over the 8th edition of cTNM staging.</description><subject>Cancer Research</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Original Article – Cancer Research</subject><subject>Small cell lung carcinoma</subject><subject>Statistical analysis</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUFrFDEYhoMouLb-AU8BL16m_TLZTJKjrN1aaKuHbS8iIZP5sk6ZyWyTTEtv_vRmu4LgwUvCF57n5SMvIR8YnDAAeZoAlryuoGYVcKl19fiKLNj-iXEuXpMFMMkqUbPmLXmX0h2UWch6QX5fYbbtNPSOWpf7B6R5Hqc50odpmEek97MNufc9dnQK9AdT65_rL-f0-9nmdLWhfo75F0aacrQvVKKb66sy2i3Si1saplCl0Q4DdViOYQ5b6mxwRdkVAUNOx-SNt0PC93_uI3KzPtusvlaX384vVp8vK8dFnSsBTCshGt_6TrsGhO86v0QGjZQotUIlOtUoZRUT2GpoOfeOtTUAx0a3DT8inw65uzjdz5iyGfu038oGnOZkaiEbzZZayoJ-_Ae9Kz8SynaFUkpKtYR9YH2gXJxSiujNLvajjU-GgdmXYg6lmFKKeSnFPBaJH6RU4LDF-Df6P9Yzv42PZg</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Rocha, Ana Luísa Gomes</creator><creator>da Conceição, Mauro Alessandro Monteiro</creator><creator>da Cunha Sequeira Mano, Francisco Xavier Proença</creator><creator>Martins, Helder Carvalho</creator><creator>Costa, Gracinda Maria Lopes Magalhães</creator><creator>Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa</creator><creator>Lapa, Paula Alexandra Amado</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7836-8161</orcidid><orcidid>https://orcid.org/0000-0002-2014-0399</orcidid><orcidid>https://orcid.org/0000-0003-3051-4152</orcidid><orcidid>https://orcid.org/0000-0002-4964-9746</orcidid><orcidid>https://orcid.org/0000-0001-9855-0454</orcidid><orcidid>https://orcid.org/0000-0003-3270-0119</orcidid></search><sort><creationdate>20211201</creationdate><title>Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients</title><author>Rocha, Ana Luísa Gomes ; da Conceição, Mauro Alessandro Monteiro ; da Cunha Sequeira Mano, Francisco Xavier Proença ; Martins, Helder Carvalho ; Costa, Gracinda Maria Lopes Magalhães ; Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa ; Lapa, Paula Alexandra Amado</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-50198556fbfd9c605fddf4e10677e798e85d8688a815eb90b33fc1b2003e69b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer Research</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Original Article – Cancer Research</topic><topic>Small cell lung carcinoma</topic><topic>Statistical analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rocha, Ana Luísa Gomes</creatorcontrib><creatorcontrib>da Conceição, Mauro Alessandro Monteiro</creatorcontrib><creatorcontrib>da Cunha Sequeira Mano, Francisco Xavier Proença</creatorcontrib><creatorcontrib>Martins, Helder Carvalho</creatorcontrib><creatorcontrib>Costa, Gracinda Maria Lopes Magalhães</creatorcontrib><creatorcontrib>Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa</creatorcontrib><creatorcontrib>Lapa, Paula Alexandra Amado</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rocha, Ana Luísa Gomes</au><au>da Conceição, Mauro Alessandro Monteiro</au><au>da Cunha Sequeira Mano, Francisco Xavier Proença</au><au>Martins, Helder Carvalho</au><au>Costa, Gracinda Maria Lopes Magalhães</au><au>Dos Santos Oliveiros Paiva, Bárbara Cecília Bessa</au><au>Lapa, Paula Alexandra Amado</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><date>2021-12-01</date><risdate>2021</risdate><volume>147</volume><issue>12</issue><spage>3601</spage><epage>3611</epage><pages>3601-3611</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
This study aimed to assess whether the whole body metabolic active tumour volume (MTV
WB
), quantified on staging [
18
F]FDG PET/CT, could further stratify stage IV non-small cell lung cancer (NSCLC) patients.
Methods
A group of 160 stage IV NSCLC patients, submitted to staging [
18
F]FDG PET/CT between July 2010 and May 2020, were retrospectively evaluated. MTV
WB
was quantified. Univariate and multivariate Cox regressions were carried out to assess correlation with overall survival (OS). C-statistic was used to test predictive power. Kaplan–Meier survival curves with Log-Rank tests were performed to compute statistical differences between strata from dichotomized variables and to calculate the estimated mean survival times (EMST). Survival rates at 1 and 5 years were calculated.
Results
MTV
WB
was a statistically significant predictor of OS on univariate (
p
< 0.0001) and multivariate analyses (
p
< 0.0001). The multivariate model with MTV
WB
(Cindex ± SE = 0.657 ± 0.024) worked significantly better as an OS predictor than the cTNM model (Cindex ± SE = 0.544 ± 0.028) (
p
= 0.003). An EMST of 29.207 ± 3.627(95% CI 22.099–36.316) months and an EMST of 10.904 ± 1.171(95% CI 8.609–13.199) months (Log-Rank
p
< 0.0001) were determined for patients with MTV
WB
< 104.3 and MTV
WB
≥ 104.3, respectively. In subsamples of stage IVA (cut-off point = 114.5) and IVB patients (cut-off point = 191.1), statistically significant differences between EMST were also reported, with
p-values
of 0.0001 and 0.0002, respectively. In both substages and in the entire cohort, patients with MTV
WB
≥ cut-off points had lower EMST and survival rates.
Conclusion
Baseline MTV
WB
, measured on staging [
18
F]FDG PET/CT, further stratifies stage IV NSCLC patients. This parameter is an independent predictor of OS and provides valuable prognostic information over the 8th edition of cTNM staging.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00432-021-03799-w</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7836-8161</orcidid><orcidid>https://orcid.org/0000-0002-2014-0399</orcidid><orcidid>https://orcid.org/0000-0003-3051-4152</orcidid><orcidid>https://orcid.org/0000-0002-4964-9746</orcidid><orcidid>https://orcid.org/0000-0001-9855-0454</orcidid><orcidid>https://orcid.org/0000-0003-3270-0119</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2021-12, Vol.147 (12), p.3601-3611 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2576914977 |
| source | SpringerNature Journals |
| subjects | Cancer Research Hematology Internal Medicine Lung cancer Medicine Medicine & Public Health Metabolism Non-small cell lung carcinoma Oncology Original Article – Cancer Research Small cell lung carcinoma Statistical analysis Tumors |
| title | Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T04%3A55%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20active%20tumour%20volume%20quantified%20on%20%5B18F%5DFDG%20PET/CT%20further%20stratifies%20TNM%20stage%20IV%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Rocha,%20Ana%20Lu%C3%ADsa%20Gomes&rft.date=2021-12-01&rft.volume=147&rft.issue=12&rft.spage=3601&rft.epage=3611&rft.pages=3601-3611&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-021-03799-w&rft_dat=%3Cproquest_cross%3E2588778406%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2588778406&rft_id=info:pmid/&rfr_iscdi=true |